Dreieich, Germany

Axel Angermann



 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Axel Angermann: Innovator in Sialyltransferase Production

Introduction

Axel Angermann is a notable inventor based in Dreieich, Germany. He has made significant contributions to the field of biochemistry, particularly in the production and purification of sialyltransferase polypeptides. His work has implications for the development of therapeutic proteins, showcasing the intersection of innovation and healthcare.

Latest Patents

Angermann holds a patent for a method of producing and purifying an active soluble sialyltransferase. This invention specifically relates to the N-Acetylgalactosamine (Gal NAc)-α-2,6-sialyltransferase I (ST6GalNAcI) polypeptide. The patented method involves producing the sialyltransferase polypeptide in Chinese Hamster Ovary (CHO) cells and purifying it through a series of chromatography steps. This process results in a high yield of a highly pure and active sialyltransferase polypeptide, which can be utilized for the glycosylation of therapeutic proteins such as G-CSF.

Career Highlights

Throughout his career, Angermann has worked with prominent companies in the pharmaceutical and biotechnology sectors. Notable among these are Biogenerix GmbH and Ratiopharm GmbH. His experience in these organizations has contributed to his expertise in the field of biochemistry and innovation.

Collaborations

Angermann has collaborated with several professionals in his field, including Christian Scheckermann and Karsten Schmidt. These collaborations have likely enhanced his research and development efforts, leading to advancements in his patented methods.

Conclusion

Axel Angermann's contributions to the field of sialyltransferase production exemplify the importance of innovation in biochemistry. His patented methods not only advance scientific knowledge but also hold potential for significant applications in therapeutic protein development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…